Valuation: SpringWorks Therapeutics, Inc.

Market Cap 3.54B 3.1B 2.86B 2.67B 5.03B 335B 5.12B 34.32B 13.32B 165B 13.3B 13.01B 576B P/E 2023
-7.09x
P/E 2024 -10.4x
Enterprise Value 3.09B 2.7B 2.49B 2.33B 4.38B 292B 4.46B 29.92B 11.61B 144B 11.6B 11.34B 502B EV / Sales 2023
362,507,725x
EV / Sales 2024 11,654,155x
Free-Float
97.93%
Yield 2023 *
-
Yield 2024 -
3 years 18
Extreme 18
62
5 years 13.6
Extreme 13.6
89.75
10 years 13.6
Extreme 13.6
96.48
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer - 2022-12-31
Compliance Officer - 2021-12-31
Investor Relations Contact - 2018-07-31
Date Insider Type Main position Quantity % Market Cap.
25-06-30Issuer sale

Chief Technology Officer

151,946 0.2028%
25-06-30Issuer sale

Head of Human Resources

305,920 0.4082%
25-06-30Issuer sale

Director

85,011 0.1134%
Change 5-day change 1-year change 3-year change Capi.($)
+0.02%-.--%-.--%+79.21% 3.54B
-1.31%+0.89%+18.77%-13.22% 63.44B
-0.57%+4.09%+56.93%+222.66% 56.98B
-3.94%+39.10%+39.10%+39.10% 41.58B
+2.94%+2.64%-50.46%-57.27% 38.01B
-0.26%+9.57%+72.04%-24.15% 31.9B
+0.47%+14.80%+153.82%-42.36% 27.79B
-1.13%+8.58%+66.46%+82.10% 22.65B
-0.56%+4.05%+1.53%+168.92% 17.64B
-0.13%-0.94%+60.31%+119.58% 16.49B
Average -0.45%+4.59%+41.85%+57.46% 32B
Weighted average by Cap. -0.63%+4.41%+41.38%+51.38%

Financials

2023 2024
Net sales 5.45 4.77 4.4 4.11 7.74 515.02 7.87 52.79 20.5 254.15 20.46 20.01 885.38 191.59 167.7 154.8 144.4 272.08 18.12K 276.94 1.86K 720.89 8.94K 719.8 703.73 31.14K
Net income -325M -285M -263M -245M -462M -30.74B -470M -3.15B -1.22B -15.17B -1.22B -1.19B -52.84B -258M -226M -209M -195M -367M -24.41B -373M -2.5B -971M -12.04B -970M -948M -41.96B
Net Debt -656M -574M -530M -494M -931M -61.98B -948M -6.35B -2.47B -30.59B -2.46B -2.41B -107B -454M -397M -367M -342M -645M -42.93B -656M -4.4B -1.71B -21.18B -1.71B -1.67B -73.8B
Logo SpringWorks Therapeutics, Inc.
SpringWorks Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer. The Company developed and is commercializing OGSIVEO (nirogacestat) as a Food and Drug Administration (FDA)-approved medicine for adults with desmoid tumors and GOMEKLI (mirdametinib) as an FDA-approved medicine for both adults and children with neurofibromatosis type I associated plexiform neurofibromas (NF1-PN). It is also advancing a diverse portfolio of novel targeted therapy product candidates for patients with both solid tumors and hematological cancers. Brimarafenib is an investigational oral, small molecule, next-generation RAF dimer inhibitor that the Company is advancing in the clinic. SW-682 is an investigational oral, small molecule TEA Domain (TEAD), inhibitor that is evaluating in Hippo-mutant solid tumors. SW-3431 is an investigational, potentially first-in-class, small molecule activator of Protein Phosphotase 2A (PP2A), complexes.
Employees
368
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B
  1. Stock Market
  2. Stocks
  3. SWTX Stock